Today we announced the first patient has been enrolled in the Phase 2 HORIZON study of TNX-102 SL for the treatment of #majordepressivedisorder. Learn more: https://t.co/ocXQJDqv7e
#MDD#Tonix
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD) $TNXP, #TonixPharmaceuticals, #TonixPharma, #Tonix https://t.co/UbKI2TJh9i
$TNXP - Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD) - https://t.co/mIvxn0qlOn
$TNXP | Raymond James Initiates Tonix Pharma at Strong Buy with $26.00 PT on TONMYA Commercial Launch Inflection
Raymond James starts bullish as TONMYA access expansion and early commercial traction drive potential upside re-rating.
@ripster47 | @TENETTRADEGROUP | @TenetCharts
Complex conditions like fibromyalgia don't always follow a linear path, and responsive care can't be built on that premise. Today in @RealClearHealth, I outline how policy and research can accelerate a shift in better treating invisible conditions and chronic illnesses:
https://t.co/krntEoM7jA
Tonix published Phase 1 clinical data for TNX-1500 in the peer-reviewed Journal of Clinical Immunology. Read more about our Phase 2 ready, investigational, anti-CD40L monoclonal antibody: https://t.co/bH6j5DnHvd
#Tonix#Immunology#KidneyTransplant
@davidji84082521@SethLederman $TNXP
Here you go. Note after a huge spike on the week of May 1, this week's normally fall back a bit, but delta, ie, refill numbers increase in number than I expected.
all in all, a healthy grow intact.
Thanks to @Lymealliance for hosting a symposium focused on the latest advances in Lyme last week! We appreciated the opportunity to sponsor the event and present on our investigational monoclonal antibody, TNX-4800.
#LymeDisease#LymeDiseaseAwarenessMonth
Another major partnership for $RZLV 🚀
Rezolve AI just announced a multi-million dollar strategic partnership with Enhanced Group (NYSE: ENHA) to power AI-native fan engagement, digital experiences, and future AI-driven healthcare features across the Enhanced ecosystem.
Rezolve AI will power:
• AI-enabled fan engagement
• Mobile-first digital experience for Enhanced Games Las Vegas
• Conversational AI concierge
• Future tele-health & AI Doctor capabilities
• AI-driven personalization ecosystem
This comes after partnerships with Microsoft, Google, TCS, Tether and others.
$RZLV is rapidly expanding beyond retail into sports, healthcare-adjacent platforms, entertainment, payments, and agentic commerce. 👀🔥
$TNXP
Reacceleration indeed, the numbers don't lie.
This is the backdrop of our investment sanity which be #10bagger as more payers onboard in near future.
Also institutions and hedge have loaded up.
We look forward to our poster presentation at @ISPOR2026 on a retrospective U.S. real-world claims analysis characterizing patients with #fibromyalgia. Learn more, and see you there: https://t.co/Mo5lQXmIBO
#TNXP#Biotech#Fibromyalgia
We look forward to our poster presentation at @ISPOR2026 on a retrospective U.S. real-world claims analysis characterizing patients with #fibromyalgia. Learn more, and see you there: https://t.co/Mo5lQXmIBO
#TNXP#Biotech#Fibromyalgia
Rezolve Ai is pleased to announce a global strategic partnership designed to accelerate the worldwide rollout of agentic commerce.
Under the agreement, Tata Consultancy Services will resell Rezolve’s AI-powered commerce platform to enterprise clients globally, giving Rezolve access to one of the broadest client relationships, delivery capabilities and digital transformation footprints in the world.
🔗Press release: https://t.co/0YeqJlRWtv
#RezolveAi #StrategicPartnership #Tata #AgenticCommerce $RZLV
Today begins #FibromyalgiaAwarenessMonth💜 10 million+ adults in the U.S. live with #fibromyalgia, which causes all-encompassing impacts to their daily life. Yet they can often feel invisible or misunderstood.
#Tonix is committed to advancing scientific innovation and raising awareness for fibromyalgia to support patients, their loved ones, and their care partners.
#FibromyalgiaAwareness #ChronicPain #PatientsFirst
Today we announced the presentation of Ph. 1 data and plans for an adaptive Ph. 2 field study of TNX-4800, our investigational #monoclonalantibody for the prevention of #Lymedisease in the U.S., at @JohnsHopkinsSPH Ticks and Tickborne Diseases Symposium. https://t.co/QIkxWpTOtb
#Tonix